• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

非酒精性脂肪性肝病相关肝细胞癌的预防策略。

Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma.

机构信息

Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, Korea.

出版信息

Clin Mol Hepatol. 2023 Feb;29(Suppl):S220-S227. doi: 10.3350/cmh.2022.0360. Epub 2022 Nov 10.

DOI:10.3350/cmh.2022.0360
PMID:36353768
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10029950/
Abstract

The incidence of hepatocellular carcinoma (HCC) associated with nonalcoholic fatty liver disease (NAFLD) has been increasing worldwide, including Asia. Most patients with NAFLD-related HCC are at a much-advanced stage and older age at the time of diagnosis than those with virus-related HCC because they have not undergone HCC surveillance. This review provides an overview of the mechanism of hepatocarcinogenesis in NAFLD, preventive strategies for NAFLDrelated HCC, and strategies for the surveillance of patients with NAFLD.

摘要

非酒精性脂肪性肝病（NAFLD）相关肝细胞癌（HCC）的发病率在全球范围内包括亚洲都在不断增加。大多数 NAFLD 相关 HCC 患者在诊断时的病情比病毒相关 HCC 患者更为晚期，且年龄更大，因为他们没有接受 HCC 监测。本综述概述了 NAFLD 中肝癌发生的机制、NAFLD 相关 HCC 的预防策略以及 NAFLD 患者监测的策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f00/10029950/27b0ac3ad68b/cmh-2022-0360f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f00/10029950/27b0ac3ad68b/cmh-2022-0360f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7f00/10029950/27b0ac3ad68b/cmh-2022-0360f1.jpg

相似文献

1
Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma.非酒精性脂肪性肝病相关肝细胞癌的预防策略。
Clin Mol Hepatol. 2023 Feb;29(Suppl):S220-S227. doi: 10.3350/cmh.2022.0360. Epub 2022 Nov 10.
2
Nonalcoholic fatty liver disease and hepatocellular carcinoma.非酒精性脂肪性肝病与肝细胞癌
Metabolism. 2016 Aug;65(8):1151-60. doi: 10.1016/j.metabol.2016.01.010. Epub 2016 Jan 23.
3
AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review.AGA 临床实践更新：非酒精性脂肪性肝病患者肝细胞癌的筛查和监测：专家综述。
Gastroenterology. 2020 May;158(6):1822-1830. doi: 10.1053/j.gastro.2019.12.053. Epub 2020 Jan 30.
4
Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.非酒精性脂肪性肝病/非酒精性脂肪性肝炎与肝细胞癌。
Clin Liver Dis. 2018 Feb;22(1):201-211. doi: 10.1016/j.cld.2017.08.014.
5
Hepatocellular carcinoma and non-alcoholic fatty liver disease.肝细胞癌与非酒精性脂肪性肝病。
Hepatol Int. 2019 Nov;13(6):688-694. doi: 10.1007/s12072-019-09995-8. Epub 2019 Nov 7.
6
Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: A Problem of Growing Magnitude.非酒精性脂肪性肝病相关肝细胞癌：一个日益严重的问题。
Semin Liver Dis. 2015 Aug;35(3):304-17. doi: 10.1055/s-0035-1562949. Epub 2015 Sep 17.
7
Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma.筛查和干预措施以预防非酒精性脂肪性肝病/非酒精性脂肪性肝炎相关肝细胞癌。
World J Gastroenterol. 2023 Jan 14;29(2):286-309. doi: 10.3748/wjg.v29.i2.286.
8
β-ionone inhibits nonalcoholic fatty liver disease and its association with hepatocarcinogenesis in male Wistar rats.β-紫罗兰酮抑制非酒精性脂肪性肝病及其与雄性 Wistar 大鼠肝癌发生的关联。
Chem Biol Interact. 2019 Aug 1;308:377-384. doi: 10.1016/j.cbi.2019.05.046. Epub 2019 May 28.
9
Should Patients With NAFLD/NASH Be Surveyed for HCC?非酒精性脂肪性肝病/非酒精性脂肪性肝炎患者应筛查肝细胞癌吗？
Transplantation. 2019 Jan;103(1):39-44. doi: 10.1097/TP.0000000000002361.
10
Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.非酒精性脂肪性肝病相关肝细胞癌：日益受到关注。
Indian J Med Res. 2019 Jan;149(1):9-17. doi: 10.4103/ijmr.IJMR_1456_17.

引用本文的文献

1
Food Nutrients and Bioactive Compounds for Managing Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comprehensive Review.用于管理代谢功能障碍相关脂肪性肝病的食物营养素和生物活性化合物：综述
Nutrients. 2025 Jul 3;17(13):2211. doi: 10.3390/nu17132211.
2
A Chemotherapy Response-Related Gene Signature and DNAJC8 as Key Mediators of Hepatocellular Carcinoma Progression and Drug Resistance.一种与化疗反应相关的基因特征及DNAJC8作为肝细胞癌进展和耐药性的关键介质
J Hepatocell Carcinoma. 2025 Mar 20;12:579-595. doi: 10.2147/JHC.S506706. eCollection 2025.
3
Evaluating the Role of Aspirin in Liver Disease: Efficacy, Safety, Potential Benefits and Risks.

本文引用的文献

1
Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?他汀类药物和阿司匹林用于肝癌的化学预防：现在使用还是等待进一步研究？
Clin Mol Hepatol. 2022 Jul;28(3):380-395. doi: 10.3350/cmh.2021.0366. Epub 2022 Jan 13.
2
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease.KASL临床实践指南：非酒精性脂肪性肝病的管理
Clin Mol Hepatol. 2021 Jul;27(3):363-401. doi: 10.3350/cmh.2021.0178. Epub 2021 Jun 22.
3
From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
评估阿司匹林在肝脏疾病中的作用：疗效、安全性、潜在益处及风险。
Life (Basel). 2024 Dec 23;14(12):1701. doi: 10.3390/life14121701.
4
Statins decrease the risk of hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis.他汀类药物降低代谢功能障碍相关脂肪性肝病患者肝细胞癌的风险：一项系统评价和荟萃分析。
World J Exp Med. 2024 Dec 20;14(4):98543. doi: 10.5493/wjem.v14.i4.98543.
5
Reassessing the Impact of Coffee Consumption on Liver Disease: Insights from a Large-Scale Cohort Study with IPTW Adjustment.重新评估咖啡消费对肝脏疾病的影响：基于 IPTW 调整的大规模队列研究的见解。
Nutrients. 2024 Jun 26;16(13):2020. doi: 10.3390/nu16132020.
6
Crosstalk between Epigenetics and Metabolic Reprogramming in Metabolic Dysfunction-Associated Steatotic Liver Disease-Induced Hepatocellular Carcinoma: A New Sight.代谢功能障碍相关脂肪性肝病诱导的肝细胞癌中表观遗传学与代谢重编程之间的串扰：新视角
Metabolites. 2024 Jun 8;14(6):325. doi: 10.3390/metabo14060325.
7
Recent Insights into the Biomarkers, Molecular Targets and Mechanisms of Non-Alcoholic Steatohepatitis-Driven Hepatocarcinogenesis.非酒精性脂肪性肝炎驱动的肝癌发生的生物标志物、分子靶点和机制的最新见解
Cancers (Basel). 2023 Sep 14;15(18):4566. doi: 10.3390/cancers15184566.
8
Factors associated with unrecognized cirrhosis in patients with hepatocellular carcinoma.与肝细胞癌患者未被识别的肝硬化相关的因素。
Clin Mol Hepatol. 2023 Apr;29(2):453-464. doi: 10.3350/cmh.2022.0450. Epub 2023 Feb 1.
从非酒精性脂肪性肝病到代谢相关脂肪性肝病：大浪潮还是小涟漪？
Clin Mol Hepatol. 2021 Apr;27(2):257-269. doi: 10.3350/cmh.2021.0067. Epub 2021 Mar 22.
4
Aspirin Use Is Associated with a Reduced Incidence of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.阿司匹林的使用与肝细胞癌发病率的降低有关：系统评价和荟萃分析。
Hepatol Commun. 2020 Nov 13;5(1):133-143. doi: 10.1002/hep4.1640. eCollection 2021 Jan.
5
Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis.他汀类药物的使用可降低肝细胞癌的发病率：一项更新的荟萃分析。
Cancers (Basel). 2020 Apr 3;12(4):874. doi: 10.3390/cancers12040874.
6
Statin Use and the Risk of Hepatocellular Carcinoma: A Meta-Analysis of Observational Studies.他汀类药物的使用与肝细胞癌风险：观察性研究的荟萃分析
Cancers (Basel). 2020 Mar 13;12(3):671. doi: 10.3390/cancers12030671.
7
The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis Caused by NASH.非酒精性脂肪性肝炎（NASH）进展的20%规则：NASH所致晚期纤维化和肝硬化的自然史
Hepatology. 2019 Dec;70(6):1885-1888. doi: 10.1002/hep.30946.
8
Physical Activity and the Risk of Liver Cancer: A Systematic Review and Meta-Analysis of Prospective Studies and a Bias Analysis.体力活动与肝癌风险：前瞻性研究的系统评价和荟萃分析及偏倚分析。
J Natl Cancer Inst. 2019 Nov 1;111(11):1142-1151. doi: 10.1093/jnci/djz111.
9
Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease.每日服用阿司匹林与非酒精性脂肪性肝病患者纤维化进展风险降低相关。
Clin Gastroenterol Hepatol. 2019 Dec;17(13):2776-2784.e4. doi: 10.1016/j.cgh.2019.04.061. Epub 2019 May 9.
10
Coffee consumption and liver cancer risk in Japan: a meta-analysis of six prospective cohort studies.日本的咖啡消费与肝癌风险：六项前瞻性队列研究的荟萃分析
Nagoya J Med Sci. 2019 Feb;81(1):143-150. doi: 10.18999/nagjms.81.1.143.